Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty. METHODS: In this randomized, double-blind study, we assigned 4541 patients to receive either 10 mg of oral rivaroxaban once daily, beginning after surgery, or 40 mg of enoxaparin subcutaneously once daily, beginning the evening before surgery, plus a placebo tablet or injection. The primary efficacy outcome was the composite of deep-vein thrombosis (either symptomatic or detected by bilateral venography if the patient was asymptomatic), nonfatal pulmonary embolism, or death from any cause at 36 days (range, 30 to 42). The main secondary efficacy outcome was major venous thromboembolism (proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death from venous thromboembolism). The primary safety outcome was major bleeding. RESULTS: A total of 3153 patients were included in the superiority analysis (after 1388 exclusions), and 4433 were included in the safety analysis (after 108 exclusions). The primary efficacy outcome occurred in 18 of 1595 patients (1.1%) in the rivaroxaban group and in 58 of 1558 patients (3.7%) in the enoxaparin group (absolute risk reduction, 2.6%; 95% confidence interval [CI], 1.5 to 3.7; P<0.001). Major venous thromboembolism occurred in 4 of 1686 patients (0.2%) in the rivaroxaban group and in 33 of 1678 patients (2.0%) in the enoxaparin group (absolute risk reduction, 1.7%; 95% CI, 1.0 to 2.5; P<0.001). Major bleeding occurred in 6 of 2209 patients (0.3%) in the rivaroxaban group and in 2 of 2224 patients (0.1%) in the enoxaparin group (P=0.18). CONCLUSIONS: A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patients undergoing elective total hip arthroplasty. The two drugs had similar safety profiles. (ClinicalTrials.gov number, NCT00329628.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We identified 1 RCT 317 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [317]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arthroplasty. 317-321”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [317]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationThe Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,528
Eriksson, B. I., Dahl, O. E., Rosencher, N., Kurth, A. A., van Dijk, C. N., Frostick, S. P., Prins, M. H., Hettiarachchi, R., Hantel, S., Schnee, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61445-7 · Cited by 1,116
Self-citationRoentgen Diagnosis of Venous Thrombosis in the Leg
Rabinov, K. (1972) · Archives of Surgery · doi:10.1001/archsurg.1972.04180020014004 · Cited by 740
Turpie, A. G. G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.16.1833 · Cited by 736
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Kubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 640
Eriksson, B. I., Bauer, K. A., Lassen, M. R., & Turpie, A. G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011100 · Cited by 631
Self-citationRosencher, N., Kerkkamp, H. E. M., Macheras, G., Munuera, L. M., Menichella, G., Barton, D. M., Cremers, S., Abraham, I. L., & Investigation, F. T. O. (2003) · Transfusion · doi:10.1046/j.1537-2995.2003.00348.x · Cited by 603
Eikelboom, J. W., Quinlan, D. J., & Douketis, J. D. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05249-1 · Cited by 513
Research works printed but not linked: 1
- 10.1016/s0140-6736(07)61445-7 · DOI · Paper page
Cited by
Items 201–300 of 1,000
Kubitza, D., Becka, M., Roth, A., & Mueck, W. (2012) · Journal of International Medical Research · doi:10.1177/030006051204000508 · Cited by 54
Tabatabaee, R. M., Rasouli, M. R., Maltenfort, M., & Parvizi, J. (2014) · The Journal of Arthroplasty · doi:10.1016/j.arth.2014.08.018 · Cited by 52
“Some studies have shown better efficacy for new agents such as oral direct factor Xa inhibitor over other modalities in prevention of DVT [38–41].”
BackgroundUse of New Oral Anticoagulants in Antiphospholipid Syndrome
Arachchillage, D. J., & Cohen, H. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-013-0331-5 · Cited by 55
“Following phase III international multicentre trials in a total of about 21,500 patients, dabigatran and rivaroxaban were licensed in the UK and Europe for the prevention of VTE in adults undergoing elective total hip replacement or knee replacement in 2009 [14–19].”
Agaba, P., Kildow, B. J., Dhotar, H. S., Seyler, T. M., & Bolognesi, M. P. (2017) · Journal of Orthopaedics · doi:10.1016/j.jor.2017.08.002 · Cited by 54
New oral anticoagulants: a practical guide for clinicians
Wittkowsky, A. K. (2009) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-009-0409-0 · Cited by 57
“Each trial compared rivaroxaban 10 mg once daily to enoxaparin, either in hip replacement (RECORD 1 [10], RECORD 2 [11]) or in knee replacement (RECORD 3 [12], RECORD 4 [13]).”
MethodPharmacology and mechanisms of action of new oral anticoagulants
Salem, J., Sabouret, P. F., Funck‐Brentano, C., & Hulot, J. (2014) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12091 · Cited by 56
Novel anticoagulants: general overview and practical considerations for dental practitioners
Elad, S., Marshall, J., Meyerowitz, C., & Connolly, G. (2015) · Oral Diseases · doi:10.1111/odi.12371 · Cited by 57
Wu, T., Lv, C., Wu, L., Chen, W., Lv, M., Jiang, S., & Zhang, J. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10448-2 · Cited by 54
Rivaroxaban: A Novel, Oral, Direct Factor Xa Inhibitor
Abrams, P. J., & Emerson, C. R. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.2.167 · Cited by 53
“In the RECORD1 trial, 12 cardiovascular events (three deaths) were reported in the rivaroxaban group during treatment and follow-up, and 10 events (one death) were reported in the enoxaparin group.(41) Investigators from the RECORD2 study reported eight cardiovascular events (three deaths) with rivaroxaban and four ev…”
BackgroundLützner, J., Donath, L., Tittl, L., Knoth, H., Radke, O. C., Kuhlisch, E., Stange, T., Hartmann, A., Günther, K., Weiss, N., et al. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-07-0510 · Cited by 53
Radadiya, D. K., Devani, K., Brahmbhatt, B. S., & Reddy, C. M. (2021) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002035 · Cited by 55
Migliorini, F., Maffulli, N., Velaj, E., Bell, A., Kämmer, D., Hildebrand, F., Hofmann, U. K., & Eschweiler, J. (2024) · Journal of Orthopaedics and Traumatology · doi:10.1186/s10195-023-00742-2 · Cited by 50
“In a large phase III RCT of 4433 patients, rivaroxaban 10 mg was compared with enoxaparin 40 mg daily [34].”
BackgroundFranchini, M., & Mannucci, P. M. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.004 · Cited by 53
Liew, A., Eikelboom, J. W., O'Donnell, M. J., & Hart, R. G. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.04.013 · Cited by 58
Chatterjee, S., Sharma, A., Uchino, K., Biondi‐Zoccai, G., Lichstein, E., & Mukherjee, D. (2013) · Coronary Artery Disease · doi:10.1097/mca.0000000000000031 · Cited by 54
Ning, G., Kan, S.-L., Chen, L., Shangguan, L., Feng, S., & Zhou, Y. (2016) · Scientific Reports · doi:10.1038/srep23726 · Cited by 50
Lindquist, D. E., Stewart, D. W., Brewster, A., Waldroup, C., Odle, B. L., Burchette, J. E., & El‐Bazouni, H. (2018) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029618772337 · Cited by 53
Moore, K. T., Vaidyanathan, S., Natarajan, J., Ariyawansa, J., Haskell, L. P., & Turner, K. C. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.352 · Cited by 52
Trujillo, T. C., & Dobesh, P. P. (2014) · Drugs · doi:10.1007/s40265-014-0278-5 · Cited by 56
Park, S., Kim, C., Park, Y.-S., Moon, Y., Lim, S., & Kim, S. (2015) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0000000000000336 · Cited by 49
Wilke, T., Moock, J., Müller, S., Pfannkuche, M., & Kurth, A. A. (2010) · Clinical Orthopaedics and Related Research · doi:10.1007/s11999-010-1306-8 · Cited by 52
“T. Wilke (&), S. Müller Institut für Pharmakoökonomie und Arzneimittellogistik, University of Wismar, PF 1210, 23952 Wismar, Germany e-mail: thomas.wilke@hs-wismar.de J. Moock Institut für Community Medicine, University Greifswald, Greifswald, Germany M. Pfannkuche Department for Market Access & Health Economics,…”
BackgroundPatient preferences regarding pharmacologic venous thromboembolism prophylaxis
Wong, A., Kraus, P. S., Lau, B. D., Streiff, M. B., Haut, E. R., Hobson, D. B., & Shermock, K. M. (2014) · Journal of Hospital Medicine · doi:10.1002/jhm.2282 · Cited by 48
Duggan, S. T., Scott, L. J., & Plosker, G. L. (2009) · Drugs · doi:10.2165/11200890-000000000-00000 · Cited by 52
“Rivaroxaban treatment was initiated 6–8 hours after wound closure in allRECORDstudies.([42-45]) InRECORD1, 2 and 3, enoxaparin 40mg was initiated 12 hours before surgery, and again 6–8 hours after wound closure.”
InfluentialSamama, M. M., & Gerotziafas, G. (2009) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-009-0392-5 · Cited by 54
Douxfils, J., Tamigniau, A., Châtelain, B., Goffinet, C., Dogné, J.-M., & Mullier, F. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-24 · Cited by 54
“Compared to LMWHs, these agents also proved their non-inferiority or superiority for initial treatment of venous thromboembolism and for thromboprophylaxis in patients undergoing hip or knee arthroplasty, [10-20].”
BackgroundHeparin and Its Derivatives: Challenges and Advances in Therapeutic Biomolecules
Banik, N., Yang, S.-B., Kang, T., Lim, J.-H., & Park, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910524 · Cited by 37
Kubitza, D., Berkowitz, S. D., & Misselwitz, F. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029616631427 · Cited by 49
Self-citationGuijarro, R., Montes, J., Roman, C. S., Arcelus, J. I., Barillari, G., Xiberta, X. G., & Monréal, M. (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-10-0645 · Cited by 47
An algorithm for managing warfarin resistance
Osinbowale, O. O., Malki, M. M. A., Schade, A. E., & Bartholomew, J. R. (2009) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.76a.09062 · Cited by 50
Warfarin Versus New Agents: Interpreting the Data
Ansell, J. (2010) · Hematology · doi:10.1182/asheducation-2010.1.221 · Cited by 53
The potential benefits of low-molecular-weight heparins in cancer patients
Robert, F. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-3 · Cited by 48
“Some of the new anticoagulants, such as dabigatran [111] and rivaroxaban [ 112 ,113], are orally administered drugs that have proven effective in reducing the incidence of VTE following major orthopedic surgery.”
BackgroundLassen, M. R., Gent, M., Kakkar, A. K., Eriksson, B. I., Homering, M., Berkowitz, S. D., & Turpie, A. G. G. (2012) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.94b11.28955 · Cited by 53
Self-citationBeing precise with anticoagulation to reduce adverse drug reactions: are we there yet?
Cross, B., Turner, R. M., Zhang, E. J., & Pirmohamed, M. (2024) · The Pharmacogenomics Journal · doi:10.1038/s41397-024-00329-y · Cited by 48
Anticoagulation Management: Current Landscape and Future Trends
Kholmukhamedov, A., Subbotin, D., Gorin, A. A., & Ilyassov, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051647 · Cited by 45
Rivaroxaban prevents painful cutaneous infarctions in livedoid vasculopathy
Kerk, N., Drabik, A., Luger, T., Schneider, S. W., & Goerge, T. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12100 · Cited by 46
The in vitro anticoagulant effect of rivaroxaban in children
Attard, C., Monagle, P., Kubitza, D., & Ignjatović, V. (2012) · Thrombosis Research · doi:10.1016/j.thromres.2012.07.009 · Cited by 45
“In a number of “non-inferiority” studies, rivaroxaban was shown to have a comparable safety profile to LMWH and be at a minimum “non-inferior” in efficacy [15–17].”
BackgroundHull, R. D., Yusen, R. D., & Bergqvist, D. (2009) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029609338712 · Cited by 48
Venous Thromboembolism Prophylaxis in Major Orthopedic Surgeries and Factor XIa Inhibitors
Jones, A., & Al‐Horani, R. A. (2023) · Medical Sciences · doi:10.3390/medsci11030049 · Cited by 56
The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery
Rachidi, S., Aldin, E. S., Greenberg, C. S., Sachs, B. L., Streiff, M. B., & Zeidan, A. M. (2013) · Expert Review of Hematology · doi:10.1586/17474086.2013.853430 · Cited by 47
Russell, R. D., & Huo, M. H. (2013) · The Journal of Arthroplasty · doi:10.1016/j.arth.2013.02.016 · Cited by 48
Enoxaparin: a pharmacologic and clinical review
Iqbal, Z., & Cohen, M. C. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.570261 · Cited by 47
“The efficacy and safety of rivaroxaban, a direct oral factor Xa inhibitor, for thromboprophylaxis after total hip replacement (THR) or total knee replacement (TKR) has been compared with enoxaparin in four Phase III trials, RECORD 1 -- 4 [18,70-72].”
Ageno, W., & Beyer‐Westendorf, J. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-06-0484 · Cited by 46
Morales, R., Ruff, E. S., Patronella, C. K., Mentz, H. A., Newall, G., Hustak, K. L., Fortes, P., & Bush, A. E. (2016) · Aesthetic Surgery Journal · doi:10.1093/asj/sjv243 · Cited by 45
A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents
Joppa, S., Salciccioli, J. D., Adamski, J., Patel, S. I., Wysokiński, W. E., McBane, R. D., Al‐Saffar, F., Esser, H., & Shamoun, F. E. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7020029 · Cited by 49
“For the indication of VTE/PE (dosed at 15 mg twice daily for 3 weeks followed by 20 mg daily thereafter) rivaroxaban was non-inferior compared with enoxaparin and warfarin, in two studies [92,93].”
BackgroundPeri-Procedural Management of Oral Anticoagulants in the DOAC Era
Barnes, G. D., & Mouland, E. (2018) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2018.03.002 · Cited by 44
Use of direct oral anticoagulants in daily practice.
Almarshad, F., Alaklabi, A. A., Bakhsh, E., Pathan, A. R., & Almegren, M. (2018) · Europe PMC (PubMed Central) · Cited by 50
Harbrecht, U. (2011) · Hämostaseologie · doi:10.5482/ha-1149 · Cited by 54
Garfinkel, J. H., Gladnick, B. P., Roland, N., & Romness, D. W. (2017) · The Journal of Arthroplasty · doi:10.1016/j.arth.2017.08.039 · Cited by 46
Clinical Pharmacology of Direct and Indirect Factor Xa Inhibitors
Rupprecht, H.-J., & Blank, R. (2010) · Drugs · doi:10.2165/11538030-000000000-00000 · Cited by 50
Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?
Cohen, H., & Machin, S. J. (2010) · Lupus · doi:10.1177/0961203310361355 · Cited by 45
Suen, K., Westh, R., Churilov, L. P., & Hardidge, A. J. (2017) · The Journal of Arthroplasty · doi:10.1016/j.arth.2017.04.010 · Cited by 44
No Difference Between Low- and Regular-dose Aspirin for Venous Thromboembolism Prophylaxis After THA
Faour, M., Piuzzi, N. S., Brigati, D. P., Klika, A. K., Mont, M. A., Barsoum, W. K., & Higuera, C. A. (2019) · Clinical Orthopaedics and Related Research · doi:10.1097/corr.0000000000000613 · Cited by 46
Teichman, A. L., Cotton, B. A., Byrne, J. P., Dhillon, N. K., Berndtson, A. E., Price, M. A., Johns, T. J., Ley, E. J., Costantini, T. W., & Haut, E. R. (2022) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000003854 · Cited by 43
“34,55,58 One study of two different doses of dabigatran daily versus enoxaparin daily for total hip arthroplasty (THA) showed no difference in VTE, death, or major bleeding.”
InfluentialThromboprophylaxis in patients with lower limb immobilisation – review of current status
Nokes, T. J. C., & Keenan, J. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07737.x · Cited by 43
“The two new anticoagulants: oral direct thrombin (Dabigatran) (Eriksson et al, 2007) and Xa inhibitors (Rivaroxaban) (Eriksson et al, 2008), should allow for easier application of TP in patients immobilised in below knee cast or brace.”
BackgroundDuran, A. A., Sengupta, N., Diamantopoulos, A., Forster, F., Kwong, L. M., & Lees, M. (2011) · PharmacoEconomics · doi:10.2165/11599370-000000000-00000 · Cited by 45
“ER (%) ARR (%) NNT ER (%) ARR (%) NNT Prophylaxis module([6-8])”
BackgroundMethodResultInfluentialSikka, P., & Bindra, V. (2010) · Indian Journal of Critical Care Medicine · doi:10.4103/0972-5229.76083 · Cited by 47
“Rivaroxaban has been licensed in Europe and Canada for the above indications as studies have shown it to be more efficacious and with decreased risk of major bleeding.[31-34] Apixaban has been shown to be effective for thromboprophylaxis after orthopedic surgery.”
BackgroundBuckner, T. W., Leavitt, A. D., Ragni, M. V., Kempton, C. L., Eyster, M. E., Cuker, A. C., Lentz, S. R., Ducore, J. M., Leissinger, C., Wang, M., et al. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-10-0802 · Cited by 47
Hashikata, T., Yamaoka‐Tojo, M., Namba, S., Kitasato, L., Kameda, R., Murakami, M., Niwano, H., Shimohama, T., Tojo, T., & Ako, J. (2015) · International Heart Journal · doi:10.1536/ihj.15-112 · Cited by 42
Novel Oral Anticoagulants and Their Role in Clinical Practice
Wittkowsky, A. K. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.12.1175 · Cited by 46
Rivaroxaban Use for Thrombosis Prophylaxis Is Associated With Early Periprosthetic Joint Infection
Brimmo, O. A., Glenn, M., Klika, A. K., Murray, T. G., Molloy, R. M., & Higuera, C. A. (2015) · The Journal of Arthroplasty · doi:10.1016/j.arth.2015.12.027 · Cited by 48
Kim, S., Moon, Y., Lim, S., Kim, D.-W., & Park, Y.-S. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-07-0527 · Cited by 44
Meeting the Unmet Needs in Anticoagulant Therapy
Weitz, J. I. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01461.x · Cited by 42
Popular naturally occurring antioxidants as potential anticoagulant drugs
Bijak, M., Saluk, J., Szelenberger, R., & Nowak, P. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.07.022 · Cited by 45
Rivaroxaban: An Oral Factor Xa Inhibitor
Thomas, T. F., Ganetsky, V. S., & Spinler, S. A. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.12.005 · Cited by 44
Dragoni, F., Chiarotti, F., Iori, A. P., Rocca, U. L., & Cafolla, A. (2018) · Thrombosis Journal · doi:10.1186/s12959-018-0181-5 · Cited by 41
Chan, N., Siegal, D. M., Lauw, M. N., Ginsberg, J. S., Eikelboom, J. W., Guyatt, G. H., & Hirsh, J. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1153-7 · Cited by 43
New anticoagulants and regional anesthesia
Llau, J. V., & Ferrandis, R. (2009) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e32832eb8ab · Cited by 42
Venous Thromboembolism: A Clinical Review
Osinbowale, O. O., Ali, L. A., & Chi, Y. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.03.2122 · Cited by 46
Evaluation of the Efficacy and Safety of Rivaroxaban Using a Computer Model for Blood Coagulation
Burghaus, R., Coboeken, K., Gaub, T., Kuepfer, L., Sensse, A., Siegmund, H., Weiß, W. W., Mueck, W., & Lippert, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017626 · Cited by 45
“, the 10 mg od dose was considered to provide the optimal balance between efficacy and safety. It was selected for further development in the phase III RECORD programme, which investigated the prevention of venous thromboembolism after total hip or total knee replacement”
The clinical implications of new oral anticoagulants: Will the potential advantages be achieved?
Phillips, K., & Ansell, J. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-06-0361 · Cited by 42
Wade, R., Sideris, E., Paton, F., Rice, S. J. C., Palmer, S., Fox, D., Woolacott, N. F., & Spackman, E. (2015) · Health Technology Assessment · doi:10.3310/hta19980 · Cited by 43
Guo, W., Chen, X., Tian, X., & Li, L. (2019) · Clinical Epidemiology · doi:10.2147/clep.s219335 · Cited by 41
“Among these 25 RCTs, 7 compared apixaban with conventional therapy, 5 compared dabigatran etexilate with conventional therapy,(34,39,40,43) 6 compared edoxaban with conventional therapy and 7 trial compared rivaroxaban with conventional therapy.(29,30,35,36,38,41) The characteristics of the studies included in the ana…”
Ito, Y., Maejima, Y., Nakagama, S., Shiheido‐Watanabe, Y., Tamura, N., & Sasano, T. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.09.010 · Cited by 42
New Anticoagulants for Atrial Fibrillation
Sobieraj‐Teague, M., O'Donnell, M. J., & Eikelboom, J. W. (2009) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0029-1234147 · Cited by 52
Sobieraj, D. M., Coleman, C. I., Tongbram, V., Chen, W., Colby, J. A., Lee, S., Kluger, J., Makanji, S. S., Ashaye, A. O., & White, C. M. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2012.01106.x · Cited by 46
Dutch guideline on total hip prosthesis
Swierstra, B. A., Vervest, A. M. J. S., Walenkamp, G. H. I. M., Schreurs, B. W., Spierings, P. T. J., Heyligers, I. C., van Susante, J. L., Ettema, H. B., Jansen, M. J., Hennis, P. J., et al. (2011) · Acta Orthopaedica · doi:10.3109/17453674.2011.623575 · Cited by 40
He, T., Han, F., Wang, J., Hu, Y., & Zhu, J. (2021) · PLoS ONE · doi:10.1371/journal.pone.0250096 · Cited by 40
Venous Thromboembolism (VTE) Prophylaxis for Hip and Knee Arthroplasty: Changing Trends
Budhiparama, N. C., Abdel, M. P., Ifran, N. N., & Parratte, S. (2014) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-014-9207-1 · Cited by 42
Potential antidotes for reversal of old and new oral anticoagulants
Suryanarayan, D., & Schulman, S. (2014) · Thrombosis Research · doi:10.1016/s0049-3848(14)50026-6 · Cited by 42
“Rivaroxaban was evaluated in a series of clinical trials in patients undergoing major orthopedic surgery for thromboprophylaxis and demonstrated higher efficacy compared to enoxaparin with similar bleeding rates [17-20].”
BackgroundTrkulja, V., & Kolundžić, R. (2010) · Croatian Medical Journal · doi:10.3325/cmj.2010.51.113 · Cited by 41
A New Generation of Oral Direct Anticoagulants
Soff, G. A. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.242834 · Cited by 46
Pellegrini, V. D., Eikelboom, J. W., Evarts, C. M., Franklin, P. D., Garvin, K. L., Goldhaber, S. Z., Iorio, R. R., Lambourne, C. A., Magaziner, J. S., & Magder, L. S. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-060000 · Cited by 42
Kubitza, D., Becka, M., Mück, W. M., & Schwers, S. (2012) · Pharmaceuticals · doi:10.3390/ph5030279 · Cited by 44
“demonstrated consistent efficacy and reassuring safety in large-scale clinical trials [10,15–21].”
BackgroundAnticoagulation in the Elderly
Robert‐Ebadi, H., & Righini, M. (2010) · Pharmaceuticals · doi:10.3390/ph3123543 · Cited by 42
“the risk of major bleeding [93,94,95].”
Kröll, D., Nett, P. C., Rommers, N., Borbély, Y., Deichsel, F., Nocito, A., Zehetner, J., Kessler, U., Fringeli, Y., Alberio, L., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.15241 · Cited by 40
Venous thromboembolism in orthopedic surgery: Global guidelines
Uzel, K., Azboy, İ., & Parvizi, J. (2023) · Acta Orthopaedica et Traumatologica Turcica · doi:10.5152/j.aott.2023.23074 · Cited by 42
“55 When rivaroxaban was used after TKA, the DVT rate was higher at 6.3%-6.9% compared to 9.0%-18.2% for LMWH, while the non-fatal PE rate was lower at 0%-0.3% compared to 0.5% for LMWH. 56 Apixaban has been shown to have lower rates of DVT and nonfatal PE compared to LMWH when used for VTE…”
ResultInfluentialSaraf, K., Morris, P., Garg, P., Sheridan, P. J., & Storey, R. F. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2014-132605 · Cited by 42
Apixaban: A novel oral inhibitor of factor Xa
Nutescu, E. A. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110418 · Cited by 39
Cohen, A. T., Drost, P., Marchant, N., Mitchell, S., Orme, M. E., Rublee, D. A., Simon, T. A., & Sutton, A. J. (2012) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612437579 · Cited by 46
Influences of Obesity and Bariatric Surgery on the Clinical and Pharmacologic Profile of Rivaroxaban
Moore, K. T., & Kröll, D. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.05.011 · Cited by 39
What Surgeons Should Know About Non–Vitamin K Oral Anticoagulants: A Review
Verma, A., Ha, A. C. T., Rutka, J. T., & Verma, S. (2018) · JAMA Surgery · doi:10.1001/jamasurg.2018.0374 · Cited by 42
Pineo, G. F., Gallus, A. S., Raskob, G. E., CHEN, D., Ramirez, L. M., Ramacciotti, E., Lassen, M. R., & Wang, L. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12109 · Cited by 42
The prevention of hospital‐acquired venous thromboembolism in the United Kingdom
Hunt, B. J. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07517.x · Cited by 45
“…in TP after elective hip [Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism (RECORD) 1, Eriksson et al, 2008: RECORD 2, Kakkar et al, 2008] and knee surgery (RECORD 3, Lassen et al, 2008) with a meta-analysis showing a further 70– 80%…”
BackgroundPrevention and management of TURP-related hemorrhage
Kavanagh, L. E., Jack, G. S., & Lawrentschuk, N. (2011) · Nature Reviews Urology · doi:10.1038/nrurol.2011.106 · Cited by 39
“Dabigatran, a thrombin inhibitor, and rivaroxaban, which inhibits factor Xa, have both been studied in large, double-blind randomized phase III trials for the prevention of venous thromboembolism and demonstrated equivalent efficacy to warfarin with lower rates of major hemorrhage”
BackgroundOral factor Xa inhibitors for the prevention of stroke in atrial fibrillation
Piccini, J. P., Lópes, R. D., & Mahaffey, K. W. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32833a524f · Cited by 38
Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications
Barrios, V., & Escobar, C. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.172 · Cited by 40
Yoshida, R. D. A., Yoshida, W. B., Maffei, F. H. D. A., Dib, R. E., Nunes, R., & Rollo, H. A. (2013) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2012.06.010 · Cited by 41
Direct oral anticoagulants and venous thromboembolism
Franchini, M., & Mannucci, P. M. (2016) · European Respiratory Review · doi:10.1183/16000617.0025-2016 · Cited by 40
Lipid-based carriers for controlled delivery of nitric oxide
Elnaggar, M. A., Subbiah, R., Han, D. K., & Joung, Y. K. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1285904 · Cited by 39
“to use NOmicrobubbles as a potential treatment for DVT [151,152].”
MethodInfluentialAnticoagulantes orales directos: puesta al día
Franco‐Moreno, A., Díaz, R. M. M., & Navarro, M. J. G. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.11.042 · Cited by 39
Metadata
- Authors
- Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., & Geerts, W.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Aarhus University Hospital (DK)
- Medical University of South Carolina (US)
- Technical University of Munich (DE)
- Leiden University Medical Center (NL)
- Queen Mary University of London (GB)
- Bayer (Germany) (DE)
- University of Toronto (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-06-26
- Volume
- 358
- Issue
- 26
- Pages
- 2765-2775
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2014491911
- Cited by
- 1,433
- References
- 25
- Citations by year
- 2026: 15 · 2025: 28 · 2024: 24 · 2023: 35 · 2022: 39 · 2021: 55 · 2020: 47 · 2019: 47 · 2018: 60 · 2017: 68 · 2016: 86 · 2015: 92 · 2014: 98 · 2013: 167 · 2012: 159
- FWCI
- 76.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IrInSubria (University of Insubria) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- rivaroxaban, enoxaparin, thromboprophylaxis, total hip arthroplasty, venous thromboembolism, deep vein thrombosis, pulmonary embolism, factor Xa inhibitors, major bleeding, postoperative anticoagulation
- MeSH terms
- Rivaroxaban, Adolescent, Adult, Aged, Aged, 80 and over, Anticoagulants, Double-Blind Method, Female, Humans, Male, Middle Aged, Morpholines, Pulmonary Embolism, Thiophenes, Enoxaparin, Arthroplasty, Replacement, Hip, Venous Thrombosis, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.